ATLANTA, GA -- (MARKET WIRE) -- 04/28/2006 -- AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, and Rob Scott, M.D., Senior Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer, are scheduled to present a company overview and update at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, May 3, 2006, at 4:30 p.m. EDT at The Mandarin Oriental Miami in Miami, Florida.

A live audio webcast of the presentation will be available on the Company's Investor Relations website at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=AGIX&item_id=1297976.

A replay of the presentation will be available on the AtheroGenics website for 14 days.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit www.atherogenics.com.